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S292 Poster Session IIirradiation based (TBI) reduced intensity conditioning regimens
for allogeneic hematopoietic cell transplant (alloHCT). We pres-
ent results of the first 10 patients receiving a novel conditioning
regimen comprising fludarabine 40 mg/m2/day  four, melpha-
lan 50 mg/m2  one and TBI 200 cGy  two fractions. The
goal of this reduced intensity regimen was to achieve complete
rapid complete donor lymphoid chimerism in order to promote
graft vs. malignancy effects without excess regimen related
toxicity.
Methods: Ten consecutive patients, six male and four female,
underwent reduced intensity conditioning followed by alloHCT.
The median age was 51.5 (range 5-71). Diagnoses and patient
numbers were myelodysplastic syndrome (MDS), n5 3,acute
myeloid leukemia (AML), n5 3, Non-Hodgkin lymphoma
(NHL), n5 3 and Diamond Blackfan anemia, n5 1. Stem cell
sources peripheral blood (PB), n5 8 and bone marrow, n5 2.
Donors were related n5 8 of which n were HLA matched
and unrelated, n5 4 which  were HLA matched at  loci.
Three patients were undergoing second transplants (second
allo n5 1) and prior autoHCT (n5 2). Three patients had un-
controlled malignancy at the time of transplant. The extent of
donor chimerism was assessed by flow-sorting PB for myeloid
(CD33) and lymphoid (CD3) markers followed by short tandem
repeat (STR) analysis.
Results: At a median follow up 88 days (range 14-171); nine of ten
recipients were alive at day 30. One patient died on day fifteen
post transplant with progressive disease. Six of nine patients achieved
complete donor lymphoid chimerism and seven of nine patients
achieved complete donor myeloid chimerism in peripheral blood
day 30. This is significantly faster than historical controls using
200 cGy based regimens. Of the three patients who had incomplete
donor chimerism, two had refractory malignancy (AML or MDS) at
the time of transplant and the third patient developed progressive
MDS soon after. Treatment relatedmortality at day 100 was ten per-
cent. One of the ten patients manifested grade 3-4 Bearman regimen
related toxicity.
Conclusions: Reduced intensity with Flu/Mel/TBI 400 is well tol-
erated and produces rapid donor chimerism in allogeneic stem cell
recipients.
Results
GradePatientFollow-
up
(days)Days
post
BMT% Donor
Lymphoid
Chimerism% Donor
Myeloid
Chimerism3/4
Bearman
ToxicityUncont-
rolled
Malignancy#1 128 30 100 100 No Yes
#2 58 27 100 100 No No
#3 104 30 100 100 No No
#4 98 34 100 100 No No
#5 77 33 94 75 No No
#6 171 27 95 95 Yes No
#7 78 34 100 100 No No
#8 100 30 100 100 No Yes
#9 30 30 92 100 No No
#10 14 died
day 15
NA NA Yes Yes364
A STEM CELL POTENCY, QUALITY AND RELEASE (PQR) ASSAY FOR UM-
BILICAL CORD BLOOD THAT IS COMPLIANT WITH REGULATORY GUIDE-
LINES
Rich, I.N., Hall, K., Harper, H. HemoGenix, Inc, Colorado Springs, CO
New guidelines and regulations in the U.S.A. and Europe will
require that the cell potency of cellular and gene therapy products
are determined prior to their intended use in the patient. Umbil-
ical cord blood (UCB) is a cellular therapeutic product whose po-
tency and release criteria will fall under these criteria. The presentparameters of total nucleated cell (TNC) count, viability, CD34
and CFU not only fall significantly short of what would be re-
quired, but are used post-processing, pre-cryopreservation rather
than post-thaw prior to transplantation. Furthermore, none of
these tests determine stem cell ‘‘quality’’ or potency, which is
a measure of stem cell engraftment potential (EP). The CFU as-
say, as used by the UCB community, measures the differentiation
(not proliferation) of GM progenitors, which have no stem cell
properties and therefore can only detect engraftment outcome,
i.e. time to neutrophil engraftment, but not EP. An in vitro, in-
strument-based, ATP bioluminescence potency, quality and re-
lease (PQR) assay that can be fully validated for the intended
use has been developed and tested. 24 UCB samples were tested
for proliferation status (‘‘quality’’) and potential (potency) of 2
stem cell populations, 1 primitive (HPP-SP) and the other mature
(CFC-GEMM), each at 3 cell doses, and the response compared
to the same cell populations from a UCB reference standard.
The results showed that the assay is .90% effective in predicting
EP. Testing a single stem cell population (CFC-GEMM) can lead
to a false interpretation, but a duel stem cell potency assay can
provide greater predictive value for short- and long-term EP.
Stem cell ‘‘quality’’ should also be determined using duel popula-
tions, since together with potency, acceptance limits for release
criteria can be defined. The PQR assay is a powerful and predic-
tive tool that, together with other assays, can provide the trans-
plantation decision-maker with information that has, until now,
not been possible.365
THIOTEPA (TT), BUSULFAN (BU), AND CLOFARABINE (CLO) AS A CONDI-
TIONING THERAPY FOR ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANT FOR PATIENTS WITH HIGH RISK MALIGNANCIES: EARLY
RESPONSE AND ENGRAFTMENT DATA
Worth, L.L.1, Andersson, B.S.2, Kazerooni, R.3, Petropoulos, D.1,
Kelly, S.S.1, Lee, D.A.1, Du, M.1, Madden, T.L.3, deLima, M.J.2,
Champlin, R.E.2, Cooper, L.J.N.1 1M.D. Anderson Cancer Center, Hous-
ton, TX; 2M.D. Anderson Cancer Center, Houston, TX; 3M.D. Anderson
Cancer Center, Houston, TX
Introduction: Fludarabine (F) and Busulfan (Bu) are commonly
used together in transplantation conditioning regimens. To im-
prove on this combination, we substituted Clofarabine (Clo) for
F for its improved antileukemic activity. In addition, we added
Thiotepa (TT) as a polyfunctional alkylating agent recognized
for its antileukemic activity and its ability to cross the blood
brain barrier. We investigated TT+ (IV) Bu + Clo as a condition-
ing regimen for advanced malignancies using a variety of stem
cell sources.
Methods: Patients (pts) received TT 5 mg/kg over 1 hr on d -8. Bu
was given IV over 3 h to a daily AUC of 5,000 mcMol-min +/-10%
on d -5 to -3. Clo 40 mg/m2 was infused over 1 hr daily on d -6 to -3.
All 9 pts are evaluable for engraftment and survival beyond d +30.M/
F: 4/5. Median age was 22 (range 6-60). Five pts had AML [relapse
refractory/Flt3+/3rd transplant, CR1 h/o leptomeningeal disease,
MDS/AML (CR2), CR4 (3rd BMT) and CR7 (3rd BMT)]. Others
hadT-cell PLL (2), ALL (CR3), CLL (3rd relapse-refr). GVHDpro-
phylaxis was tacrolimus and mini-MTX or tacrolimus and MMF
[cord blood (CB) recipients]. Those with one Ag-mism or unrelated
grafts received rabbit-ATG. Stem cell sources included cord (4 db
CB; 1 single CB); MUD-apheresis (2), MUD-BM (1), MSD-apher-
esis (1).
Results: All pts engrafted neutrophils at a median of 14 d (10-25),
and platelets at a median of 42 d (CB) and 12 d (PB/BM), respec-
tively. 8 of the 9 pts are $60 days post transplantation, and the re-
maining pt  30 days. Esophagitis (max grade 2) was the most
common regimen related toxicity (RRT).Transient,mild hyperbilir-
ubinemia from RRT occurred in 5 pts. (med 3.6 mg/dl; range
2 – 9.1). Deaths (2) were due to GVHD (d +56) and infection (d
+56). Two pts relapsed (d +59, d +87). PB microsatellite chimerism
around day +30 showed 100% donor-derived T cell and myeloid
cells in 8 pts. One had mixed chimerism (3% recipient T cells).
Poster Session II S293Conclusion: This novel regimen is safe. There were no regimen-
related deaths in this high-risk pt population. All evaluable pts
achieved a CR. Engraftment in recipients of CB transplants was
rapid. This regimen demonstrates promising anti-leukemic effects.
Chemotherapy alone regimens can provide a safe and effective con-
trol of disease, and also demonstrate that TBI is not necessary to en-
sure engraftment in CB recipients. This protocol warrants further
investigation.366
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYE-
LOFIBROSIS: SINGLE CENTER EXPERIENCE
Nishihori, T.1, Perkins, J.1,3, Pidala, J.1,3, Roman, J.1, Kim, J.2,
Fernandez, H.1,3, Anasetti, C.1,3, Kharfan-Dabaja,M.A.1,3 1H. LeeMof-
fitt Cancer Center and Research Institute, University of South Florida,
Tampa, FL; 2H. Lee Moffitt Cancer Center and Research Institute, Uni-
versity of South Florida, Tampa, FL; 3University of South Florida,
Tampa, FL
Allogeneic hematopoietic stem cell transplantation (alloHCT)
is a curative treatment option for myelofibrosis. Reduced-toxicity
conditioning regimens have been utilized and reported to be fea-
sible. We report a series of 18 patients with myelofibrosis who
underwent alloHCT with either reduced-toxicity or myeloabla-
tive regimens from 2000 to 2008. Ten (56%) were male and
median age at allograft was 55.5 (range 23-63) years. Seven
(39%) had Dupriez score of 1 (intermediate-risk) and 11
(61%) had the score of 2 (high-risk). Reduced-toxicity regimen
consisted of pharmacokinetic-targeted IV busulfan plus fludara-
bine [t-IV Bu/Flu] (n5 14) or fludarabine plus melphalan
[Flu/Mel] (n5 1). Myeloablative conditioning included busulfan
plus cyclophosphamide [Bu/Cy] (n5 2) or cyclophosphamide
plus total body irradiation [Cy/TBI] (n5 1). Graft-versus-host
disease (GVHD) prophylaxis was either tacrolimus-based regi-
men (n5 15) or cyclosporine-based (n5 3). The graft sources
were from MRD5 9 (50%), MUD5 8 (44%), and MMUD5 1
(B Ag). Four (22%) pts received bone marrow grafts and other
14 cases were G-CSF-mobilized PBSC. Median CD34+ cell
dose was 9.93  106 cells/kg. Median days to ANC$ 500
cells/mL and PLAT$ 20,000/mL were 17 (range 15-28) days
and 18 (range 8-213) days, respectively. All patients with t-IV
Bu/Flu achieved platelet engraftment within 30 days. Median
donor bone marrow chimerisms by STR-PCR were 97.5 (range
91-100: n5 14) % on day 30, 99.5 (range 92-100: n5 12) % on
day 90, and 100 (range 67-100: n5 10) % on day 180. One pa-
tient with Flu/Mel conditioning received second infusion of cells
on day 89 due to graft failure. Acute GVHD (max grade)
were 0 (n5 7), 1 (n5 3), 2 (n5 4), and 3 (n5 4). Overall sur-
vival was 52.8% with a median follow-up of 14.5 months (range
3-62 months). Two patients who received myeloablative regi-
mens (Cy/TBI and Bu/Cy) developed interstitial pneumonitis
and diffuse alveolar hemorrhage. One patient progressed to
acute myeloid leukemia post transplant. The causes of non-re-
lapse mortality were infections (57%) and GVHD (43%). In
conclusion, t-IV Bu/Flu is a feasible regimen for the treatment
of myelofibrosis and it shows encouraging hematopoietic en-
graftment even in high-risk myelofibrosis.Chimerism at different time points
Median (range) %
Chimerism
by STR-PCR Day 30 Day 90 Day 180CD3 58.5 (44-100) 64.5 (45-100) 83.5 (37-100)
CD33 100 (100) 100 (100) 100 (45-100)
Unsorted BM 97.5 (91-100) 99.5 (92-100) 100 (67-100)367
LOWDOSE ALEMTUZUMAB IN VIVO CONFERS AN EFFICIENT GVHD PRO-
PHYLAXIS PROTOCOL IN SIBLING AND MATCHED UNRELATED HCT
Spyridonidis, A., Liga, M., Karakantza, M., Triantafyllou, E.,
Zoumbos, N. Patras University Hospital, Patras, Greece
Despite standard CyA/MTX GvHD prophylaxis, severe acute
GVHD occurs after 35% of matched sibling HCT. MTX is asso-
ciated with mucositis, delayed engraftment and pulmonary toxicity.
Campath anti-CD52 antibody may reduce GvHD by targeting lym-
phocytes and dendritic cells. Studies with high doses (100 mg) of the
humanized Campath1H (alemtuzumab) revealed increased inci-
dence of relapse and severe viral infections. We report our single
centre experience of low dose (20-10 mg) alemtuzumab as GvHD
prophylaxis in 26 consecutive matched sibling (n5 12), related (1)
or unrelated transplantations (13) performed during 1/2007-6/
2009. Median pt age was 36y (17-59). Diagnoses were AML(15),
ALL(8), MDS-RAEB(1), T-NHL (1), PNH (1). 20 pts were trans-
planted in CR1 and 6 with advanced disease. Conditioning was
BuCy5 12, TBI/VP16/Cy5 5, Flu/BCNU/Melphalan(FB/M) or
FB + Thiotepa5 8,HDARA-C + FB/M5 1. All pts received periph-
eral blood stem cells. The first 11 pts received for GvHDprophylaxis
iv alemtuzumab 20 mg absolute (10 mg on d-2 and d-1), the next 5
pts received 15 mg (10 mg d-2, 5 mg d-1) and the last 10 pts received
total 10 mg alemtuzumab (5 mg on d-2 and d-1). All pts engrafted
promptly (WBC. 1000/ml on d + 14 (9-19), PLT. 50000/ml on
d + 12(7-19)) and revealed complete BM and PB chimerism on
d + 30, except one with refractory disease. Two patients who discon-
tinued CyA on d + 25 (incompliance) and d + 30 (refractory disease)
experienced steroid/ATG resistant, fatal GvHD. From the remain-
ing pts, none revealed gut or liver aGvHD, whereas 10pts (38.5%)
experienced steroid-sensible skin GvHD St I-II between d + 12-
d + 57 (median d + 17). 16 pts revealed CMV reactivation but no
CMV disease occurred. CyA could be discontinued in all evaluable
pts at median on d + 120 (25-210). 8 out of 20 evaluable pts (40%)
revealed mild skin chronic GvHD, 2 moderate skin cGvHD which
resolved with steroids and one extensive skin and liver GvHD. After
a median follow up of 323 days (24-902), 17/26 pts are alive (65.4%)
and in CR and 9 died (relapse n5 6, TRM n5 3). From the 6 pts
who died due to relapse, 4/6 were at advanced stage (.CR-1) at
transplant, 5/6 underwent sibling HCT and 5/6 received the higher
(20 mg) Campath dose. Median Karnofsky is 100% and only 1 pt re-
ceives steroids for skin cGvHD. In conclusion, in vivo low dose
Campath confers an efficient GvHD prophylaxis. Campath 10 mg
seems to be the optimal schedule for efficient GvHD prophylaxis
without compromising relapse in sibling and matched unrelated
HCT.368
STABLE MIXED DONOR-DONOR CHIMERISM AFTER DOUBLE CORD
BLOOD TRANSPLANTATION
Berglund, S.1,2, Okas, M.1,2, Gertow, J.2, Uhlin, M.2, Mattsson, J.1,2
1Karolinska University Hospital Huddinge, Stockholm, Sweden; 2Karo-
linska Institutet, Karolinska University Hospital, Stockholm, Sweden
Double cord blood transplantation (DCBT) has been used in-
creasingly and has proven to be both safe and efficacious. In chime-
rism analysis, previous studies have[ indicated single unit
predominance early after DCBT. In the present study, we evaluated
the chimeric pattern in T-, B- and myeloid cells using PCR-based
chimerism analysis in seven patients after DCBT: five patients had
acute leukemia and two had lymphoma. Five patients received mye-
loablative conditioning and two patients were given reduced inten-
sity conditioning. All patients received antithymocyte globulin
(ATG) beforeDCBT.Three of the six evaluable patients showed do-
nor–donor mixed chimerism in all cell lineages at 90 days after
DCBT. Interestingly, two patients in long-term follow-up showed
mixed donor chimerism in all cell lineages at 25 and 35 months after
DCBT, respectively. Both patients are doing clinically well. Neither
of the two developed GVHD after DCBT. In conclusion, in this
study donor–donor mixed chimerism was common after high dose
ATG and DCBT. Further studies are warranted concerning the im-
munological consequences of the phenomenon of donor–donor
mixed chimerism after DCBT.
